Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
US6869793B2 · kind B2 · utility
8Cited by
7References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 23, 1997 |
| Grant date | Mar 22, 2005 |
| Priority date | — |
| Expiry date | Sep 23, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Recombinant MVA viruses containing and/or capable of expressing dengue virus antigens and the use of such recombinant MVA for vaccination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.